Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of CDX-622
Sponsor: Celldex Therapeutics
Summary
This is a study to determine the safety of CDX-622 in healthy participants.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
85
Start Date
2024-11-01
Completion Date
2026-04
Last Updated
2026-02-23
Healthy Volunteers
Yes
Conditions
Interventions
CDX-622
Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622
Normal Saline
Up to 4 infusions or 6 SC injections of normal saline
Locations (1)
Celerion, Inc.
Tempe, Arizona, United States